Biotest Aktiengesellschaft (BIESF)
USD 32.0
(0.0%)
USD 32.0
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 912 Million EUR | 9.63% |
| 2022 | 831.9 Million EUR | 14.94% |
| 2021 | 723.8 Million EUR | 4.94% |
| 2020 | 689.7 Million EUR | 9.22% |
| 2019 | 631.5 Million EUR | 15.43% |
| 2018 | 547.1 Million EUR | -13.26% |
| 2017 | 630.7 Million EUR | 10.24% |
| 2016 | 572.1 Million EUR | 3.94% |
| 2015 | 550.4 Million EUR | -0.36% |
| 2014 | 552.4 Million EUR | 29.73% |
| 2013 | 425.8 Million EUR | 36.08% |
| 2012 | 312.91 Million EUR | -6.9% |
| 2011 | 336.09 Million EUR | 3.5% |
| 2010 | 324.73 Million EUR | -10.69% |
| 2009 | 363.59 Million EUR | 7.36% |
| 2008 | 338.67 Million EUR | 8.92% |
| 2007 | 310.94 Million EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | -100.0% |
| 2004 | 250.3 Million EUR | 1.47% |
| 2003 | 246.69 Million EUR | -5.55% |
| 2002 | 261.2 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 839.9 Million EUR | -8.6% |
| 2024 Q1 | 918.9 Million EUR | 0.76% |
| 2023 Q2 | 840.6 Million EUR | 0.18% |
| 2023 Q3 | 889.6 Million EUR | 5.83% |
| 2023 FY | 912 Million EUR | 9.63% |
| 2023 Q4 | 912 Million EUR | 2.52% |
| 2023 Q1 | 839.1 Million EUR | 0.87% |
| 2022 FY | 831.9 Million EUR | 14.94% |
| 2022 Q3 | 735.5 Million EUR | -1.04% |
| 2022 Q2 | 743.2 Million EUR | 1.16% |
| 2022 Q4 | 831.9 Million EUR | 13.11% |
| 2022 Q1 | 734.7 Million EUR | 1.51% |
| 2021 Q1 | 707.1 Million EUR | 2.52% |
| 2021 FY | 723.8 Million EUR | 4.94% |
| 2021 Q2 | 723.4 Million EUR | 2.31% |
| 2021 Q3 | 723.2 Million EUR | -0.03% |
| 2021 Q4 | 723.8 Million EUR | 0.08% |
| 2020 Q2 | 685.9 Million EUR | 6.94% |
| 2020 Q1 | 641.4 Million EUR | 1.57% |
| 2020 Q3 | 678 Million EUR | -1.15% |
| 2020 Q4 | 689.7 Million EUR | 1.73% |
| 2020 FY | 689.7 Million EUR | 9.22% |
| 2019 Q2 | 562 Million EUR | 2.05% |
| 2019 FY | 631.5 Million EUR | 15.43% |
| 2019 Q4 | 631.5 Million EUR | 5.37% |
| 2019 Q3 | 599.3 Million EUR | 6.64% |
| 2019 Q1 | 550.7 Million EUR | 0.66% |
| 2018 FY | 547.1 Million EUR | -13.26% |
| 2018 Q4 | 547.1 Million EUR | 0.9% |
| 2018 Q2 | 835.9 Million EUR | 23.45% |
| 2018 Q1 | 677.1 Million EUR | 7.36% |
| 2018 Q3 | 542.2 Million EUR | -35.14% |
| 2017 Q3 | 622.2 Million EUR | -0.86% |
| 2017 Q2 | 627.6 Million EUR | 13.43% |
| 2017 Q4 | 630.7 Million EUR | 1.37% |
| 2017 Q1 | 553.3 Million EUR | -3.29% |
| 2017 FY | 630.7 Million EUR | 10.24% |
| 2016 Q1 | 558.2 Million EUR | 1.42% |
| 2016 Q3 | 555.4 Million EUR | -1.73% |
| 2016 FY | 572.1 Million EUR | 3.94% |
| 2016 Q4 | 572.1 Million EUR | 3.01% |
| 2016 Q2 | 565.2 Million EUR | 1.25% |
| 2015 Q3 | 564.6 Million EUR | -0.63% |
| 2015 FY | 550.4 Million EUR | -0.36% |
| 2015 Q4 | 550.4 Million EUR | -2.52% |
| 2015 Q2 | 568.2 Million EUR | -0.19% |
| 2015 Q1 | 569.3 Million EUR | 3.06% |
| 2014 Q2 | 446.2 Million EUR | 2.15% |
| 2014 Q3 | 445.3 Million EUR | -0.2% |
| 2014 Q4 | 552.4 Million EUR | 24.05% |
| 2014 FY | 552.4 Million EUR | 29.73% |
| 2014 Q1 | 436.8 Million EUR | 2.58% |
| 2013 Q3 | 290.2 Million EUR | -0.96% |
| 2013 Q4 | 425.8 Million EUR | 46.73% |
| 2013 FY | 425.8 Million EUR | 36.08% |
| 2013 Q1 | 285.2 Million EUR | -8.86% |
| 2013 Q2 | 293 Million EUR | 2.73% |
| 2012 FY | 312.91 Million EUR | -6.9% |
| 2012 Q3 | 315.4 Million EUR | -5.65% |
| 2012 Q4 | 312.91 Million EUR | -0.79% |
| 2012 Q1 | 341.4 Million EUR | 1.58% |
| 2012 Q2 | 334.3 Million EUR | -2.08% |
| 2011 Q1 | 329.3 Million EUR | 1.41% |
| 2011 Q4 | 336.09 Million EUR | -12.04% |
| 2011 FY | 336.09 Million EUR | 3.5% |
| 2011 Q2 | 372.9 Million EUR | 13.24% |
| 2011 Q3 | 382.1 Million EUR | 2.47% |
| 2010 Q4 | 324.73 Million EUR | -4.43% |
| 2010 Q3 | 339.8 Million EUR | -2.24% |
| 2010 Q2 | 347.6 Million EUR | 2.48% |
| 2010 FY | 324.73 Million EUR | -10.69% |
| 2010 Q1 | 339.2 Million EUR | -6.71% |
| 2009 FY | 363.59 Million EUR | 7.36% |
| 2009 Q4 | 363.59 Million EUR | 0.0% |
| 2008 FY | 338.67 Million EUR | 8.92% |
| 2007 FY | 310.94 Million EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | -100.0% |
| 2004 FY | 250.3 Million EUR | 1.47% |
| 2003 FY | 246.69 Million EUR | -5.55% |
| 2002 FY | 261.2 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ContraFect Corporation | 32.53 Million USD | -2703.48% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -1610.909% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -9417.824% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -216235.206% |
| SQZ Biotechnologies Company | 50.03 Million USD | -1722.578% |
| Intellipharmaceutics International Inc. | 12 Million USD | -7494.452% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -1158.434% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -1445.395% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -23579.553% |
| Marizyme, Inc. | 26.67 Million USD | -3318.84% |
| Genus plc | 485 Million USD | -88.041% |
| Pharming Group N.V. | 244.07 Million USD | -273.659% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -45270.2% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -36143.288% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -23900.0% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -23726.642% |
| IMV Inc. | 37.93 Million USD | -2304.252% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -7643.122% |
| ONE Bio Corp. | 27.49 Million USD | -3216.869% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -1078.036% |
| Neon Bloom, Inc. | 1.22 Million USD | -74275.333% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -17622.382% |
| Biomind Labs Inc. | 1.49 Million USD | -60756.312% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -668.18% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -4855.602% |
| Skye Bioscience, Inc. | 14.07 Million USD | -6380.85% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -63504.492% |
| Mesoblast Limited | 188.44 Million USD | -383.962% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -641724.132% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -9534.562% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -453369.639% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -15772.405% |
| GB Sciences, Inc. | 5.41 Million USD | -16734.156% |
| MultiCell Technologies, Inc. | 1617.67 USD | -56377282.284% |
| Alpha Cognition Inc. | 7.16 Million USD | -12628.943% |
| HST Global, Inc. | 593.59 Thousand USD | -153540.626% |
| CSL Limited | 18.62 Billion USD | 95.102% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 2.51 Million USD | -36226.629% |
| Halberd Corporation | 728.71 Thousand USD | -125051.121% |
| Enzolytics Inc. | 365.26 Million USD | -149.679% |
| Resverlogix Corp. | 67.39 Million USD | -1253.196% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -108635.567% |
| argenx SE | 444.95 Million USD | -104.966% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -53108.868% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -999.656% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -24782.925% |
| Bioxytran, Inc. | 3.24 Million USD | -27965.856% |
| Zenith Capital Corp. | 27.56 Thousand USD | -3307963.405% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -24322.209% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -133853.357% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -33532.771% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 1.32 Billion USD | 31.215% |
| Kadimastem Ltd | 3.5 Million USD | -25920.959% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -1362538.019% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -9986.048% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -1714.42% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -15509.433% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -45930.198% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | 1.07 Million USD | -84403.988% |
| EV Biologics, Inc. | 2.11 Million USD | -43019.161% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -196156.071% |
| Q BioMed Inc. | 8.13 Million USD | -11113.658% |
| LadRx Corporation | 2.2 Million USD | -41344.599% |
| Cell Source, Inc. | 15.8 Million USD | -5669.7% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -2040351.047% |
| Regen BioPharma, Inc. | 5.45 Million USD | -16610.593% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -1117.298% |
| Itoco Inc. | 1.65 Million USD | -55067.374% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -44353.868% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -72327.34% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -3585.44% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -14976.872% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -7561.869% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 3.99 Million USD | -22735.709% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -382043.186% |
| NovAccess Global Inc. | 7.86 Million USD | -11501.973% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -2181770.38% |
| BioStem Technologies, Inc. | 15.9 Million USD | -5634.166% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -58123.531% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -3324363.238% |
| Qrons Inc. | 1.48 Million USD | -61160.968% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -8156.914% |
| SYBLEU INC | 681.41 Thousand USD | -133739.536% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -112660.48% |
| Rebus Holdings, Inc. | 5.24 Million USD | -17297.94% |
| Regen BioPharma, Inc. | 5.45 Million USD | -16610.593% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -14846.152% |
| Affymax, Inc. | 8.87 Million USD | -10180.69% |
| Mobile Lads Corp. | 1.31 Million USD | -69332.972% |
| International Stem Cell Corporation | 5.27 Million USD | -17182.547% |
| CytoDyn Inc. | 127.89 Million USD | -613.091% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -145631.365% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -19652.552% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -2124.607% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -3996.115% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -44928.432% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -16548.412% |
| Neutra Corp. | 973.52 Thousand USD | -93579.798% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -3043.202% |
| PureTech Health plc | 125.58 Million USD | -626.213% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -24173.88% |
| IXICO plc | 1.9 Million USD | -47892.624% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -4342.496% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -782.66% |
| CSL Limited | 18.62 Billion USD | 95.102% |
| Cellectis S.A. | 249.36 Million USD | -265.722% |